Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albendazole is a broad-spectrum benzimidazole anthelmintic used to treat a variety of parasitic worm infections, including neurocysticercosis (caused by the pork tapeworm) and cystic hydatid disease (caused by the dog tapeworm)[1][2][3][4]. It is also used for other helminth infections and has activity against some protozoa[5]. Albendazole works by binding to the colchicine-sensitive site of beta-tubulin in susceptible parasites, inhibiting microtubule polymerization. This disrupts glucose uptake and depletes glycogen stores, leading to energy depletion, immobilization, and death of the parasite[3][5][6]. The drug may also impair cell division in parasites by preventing spindle fiber formation[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on albendazole.